Corteva
CTVA
$12.14
-0.25%
Corteva is a global agricultural inputs company focused on crop protection chemistry — herbicides, insecticides, fungicides, biologicals, and plant health products — following the 2026 spin-off of its seed business (Vylor), which transformed it from an integrated seeds-and-chemistry player into a pure-play crop protection company. The business is geographically diversified, with North America contributing roughly 40% of revenue and Latin America over 30%, and it competes in an oligopolistic industry alongside a handful of global agrochemical majors where scale in R&D, regulatory registrations, and distribution is the primary moat. The investor narrative is dominated by the post-spinoff re-rating debate: bulls, including JPMorgan and KeyBanc which both upgraded to Overweight in early October 2026, argue the remaining chemistry business is undervalued and misunderstood as a standalone entity, while bears point to a steep post-separation share price collapse, negative revenue growth, and the loss of the higher-margin seed franchise. Near-term attention is squarely on Q3 results as the first clean read on the pure-play's earnings power, margin structure, and capital allocation priorities.…
CTVA
Corteva
$12.14
Related headlines
Investment Opinion: Should I buy CTVA Today?
Rating: Hold with a constructive, event-driven bias toward Buy. The core thesis is that Corteva's post-spinoff chemistry pure-play is priced at 10.59x forward EPS of $0.774 and 2.62x sales — the bottom of its own historical P/S band of 6.04x–17.54x — while the sell-side consensus (11 Buy, 2 Hold, 0 Sell; recommendation mean 1.54) carries a $17.13 average target implying +44% upside from $11.90. That gap is a bet on execution, not a validated consensus, so the rating stays at Hold until Q3 delivers the first clean read on standalone earnings power.
Supporting evidence is genuinely two-sided. On valuation, forward PE of 10.59x sits below the low-to-mid teens typical of large-cap agrochemical peers and P/B of 1.89x is near the middle of its 1.35x–2.31x historical band, while gross margin has improved sequentially from 42.35% in Q4 2025 to 51.64% in Q1 2026 to 54.35% in Q2 2026 and Q2 operating margin reached 30.02%. Against that, revenue fell 1.19% YoY to $6.379B in Q2 2026, trailing EPS is just $0.024, trailing net margin is 6.29%, and trailing FCF of $629M on a $45.6B market cap is a 1.4% FCF yield — meaning roughly 97% of the forward earnings story is undelivered. The balance sheet is the strongest leg: debt-to-equity of 0.107, current ratio of 1.43, and Q2 interest coverage near 40.7x support the 1.04% dividend (43.4% payout) and $250M/quarter buyback.
Three risks could invalidate the thesis: (1) Q3 shows the chemistry-only business cannot sustain the 30.02% operating margin without the seed franchise, forcing cuts to the $0.774 consensus EPS; (2) working-capital swings — operating cash flow of -$2.891B in Q1 2026 and -$466M in Q2 2026 — persist and starve the buyback/dividend of internal funding; (3) post-separation index and stub-holder selling keeps the shares depressed regardless of fundamentals, with UBS and Citigroup still Neutral. This Hold would upgrade to Buy if Q3 confirms operating margin above ~25% and forward EPS tracking toward $0.774, or downgrade to Sell on a break below the $11.33 October 28 low toward the $9.54 52-week low. Verdict: undervalued relative to Corteva's own history and cheap on forward earnings, but not yet proven — fairly-to-deeply undervalued only if execution holds.
Sign up to view all
CTVA 12-Month Price Forecast
Corteva is a post-spinoff dislocation story where the valuation is compelling only if the forward earnings bridge holds: at 10.59x forward EPS the stock is cheap versus agrochemical peers, but that multiple rests on a roughly 4x recovery from trailing $0.024 EPS to $0.774 consensus that no reported quarter has yet validated. The bull evidence is real — gross margin climbing to 54.35%, Q2 operating margin of 30.02%, a fortress balance sheet at 0.107 debt-to-equity, and a sell-side consensus with zero Sells and +44% implied upside — but it is forward-looking, while the bear evidence (revenue -1.19% YoY, 6.29% trailing net margin, 1.4% FCF yield, -87.48% max drawdown) is already in the numbers. The wide $13.65–$20.00 target range and Neutral stances from UBS and Citigroup confirm the market is in a show-me posture awaiting Q3. I would upgrade to bullish if Q3 confirms operating margin above ~25% and EPS tracking toward $0.774, and downgrade to bearish on a break below the $11.33 October 28 low or any cut to consensus EPS.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Corteva's 12-month outlook, with a consensus price target around $17.05 and implied upside of +40.4% versus the current price.
Average Target
$17.05
14 analysts
Implied Upside
+40.4%
vs. current price
Analyst Count
14
covering this stock
Price Range
$14 - $20
Analyst target range
Coverage is solid for a mid-cap spin-off, with 13 analysts and a distribution of 11 Buy, 2 Hold, and 0 Sell, producing a consensus recommendation of "buy" and a recommendation mean of 1.54 (where 1.0 is a strong buy). The average target price of $17.13 implies approximately +44% upside from the current $11.90, a wide gap that signals the sell-side views the post-spinoff selloff as overdone. The consensus leans clearly bullish, and the upgrade pattern supports that stance: JPMorgan moved to Overweight from Neutral on October 6, 2026, and KeyBanc moved to Overweight from Sector Weight on October 7, 2026, both citing post-spinoff undervaluation.
The full target range of $13.65 to $20.00 is wide — the low target alone implies +14.7% upside and the high target +68.1% — which signals high uncertainty about the standalone earnings power rather than strong conviction. The high target of $20.00 likely assumes successful execution of the pure-play strategy, multiple expansion toward historical P/S levels, and forward EPS delivery near the $0.774 consensus; the low target of $13.65 essentially prices in modest upside from current levels, consistent with a "show-me" stance awaiting Q3 confirmation. Notably, UBS and Citigroup remain Neutral as of October 2026, and the Motley Fool piece explicitly cautions investors to await Q3 results before acting on the upgrades — the spread between the $17.13 average and the $11.90 price is a bet on execution, not a consensus that has already been validated by reported numbers.
Bulls vs Bears: CTVA Investment Factors
The bear case currently has stronger evidence in reported numbers: revenue is declining 1.19% YoY, trailing EPS is $0.024, free cash flow yield is only 1.4%, and the stock is in an -87% drawdown with no confirmed bottom. The bull case rests almost entirely on forward-looking expectations — a 10.59x forward PE, a $17.13 average target implying +44% upside, and two October upgrades — which are credible but unvalidated by a single clean quarter of pure-play results. The single most important tension is whether the chemistry-only business can deliver the $0.774 consensus EPS and sustain its 30% Q2 operating margin without the seed franchise; if it can, the stock is deeply undervalued at 2.62x sales, and if it cannot, the trailing 41.9x PE is the reality. Until Q3 provides that first clean read, the risk/reward is asymmetric but the evidence remains speculative rather than confirmed.
Bullish
- Analyst consensus sees 44% upside: All 13 covering analysts rate CTVA a Buy or Hold (11 Buy, 2 Hold, 0 Sell) with a recommendation mean of 1.54, and the $17.13 average target implies +44% upside from $11.90. JPMorgan and KeyBanc both upgraded to Overweight in early October 2026 explicitly citing post-spinoff undervaluation, suggesting the sell-side views the selloff as a dislocation rather than a fundamental repricing.
- Forward PE of 10.59x is cheap: The forward PE of 10.59x sits below the low-to-mid teens typical of large-cap agrochemical peers, and P/S of 2.62x is at the very bottom of Corteva's own historical 6.04x–17.54x range. If consensus EPS of $0.774 materializes versus trailing $0.024, the stock is priced for a roughly 4x earnings recovery that the market is not yet willing to pay for.
- Gross margin improving through cycle: Gross margin has climbed sequentially from 42.35% in Q4 2025 to 51.64% in Q1 2026 to 54.35% in Q2 2026, and Q2 operating margin reached 30.02%. That trajectory suggests the chemistry business retains meaningful pricing power and cost discipline even before standalone cost actions are fully reflected.
- Fortress balance sheet, low leverage: Debt-to-equity of just 0.107, a current ratio of 1.43, and Q2 interest coverage of roughly 40.7x ($1.915B operating income vs. $47M interest expense) give the pure-play ample room to fund its 1.04% dividend (43.4% payout) and $250M/quarter buyback while it proves out standalone earnings.
Bearish
- Revenue is contracting, not growing: Q2 2026 revenue of $6.379B fell 1.19% year over year versus $6.456B, and the sequential pattern (Q1 up, Q2 down) shows uneven demand rather than a clean growth trajectory. Consensus revenue of $8.57B implies only modest stabilization, capping the re-rating case until the pure-play demonstrates organic volume and price gains.
- Trailing profitability is near zero: Trailing EPS of $0.024 and a trailing net margin of just 6.29% reflect a business that lost $552M in Q4 2025 and $320M in Q3 2025. The entire valuation thesis rests on a 4x earnings recovery to the $0.774 consensus, which is unproven for the chemistry-only entity.
- Loss of the seed franchise is structural: Pre-spin segment data shows Seed at $4.532B versus Crop Protection at $1.847B — the remaining business is only about 29% of disclosed segment revenue. The question is whether chemistry alone can sustain the 30.02% Q2 operating margin without the higher-margin seed contribution, and the trailing 6.29% net margin suggests that is not yet demonstrated.
- Thin free cash flow and working-capital swings: Trailing FCF is only $629M against a $45.6B market cap, a 1.4% FCF yield, and quarterly operating cash flow was -$2.891B in Q1 2026 and -$466M in Q2 2026 driven by a $4.056B working-capital outflow. Dividends and buybacks are being funded from balance-sheet capacity rather than internally generated cash.
CTVA Technical Analysis
Corteva is in a severe, structural downtrend, with the 1-year price change at -81.16% and the 3-month change at -84.51%, a decline that coincides with the October 1, 2026 price adjustment from roughly $77.65 to $12.57 reflecting the seed business separation. At the current price of $11.90, the stock sits at approximately 46.6% of its 52-week range (low of $9.54, high of $14.62), meaning it is in the lower half of its post-spinoff trading band but well off the absolute low — a positioning that reflects neither momentum leadership nor a clean capitulation bottom, but rather a market still searching for a post-separation equilibrium. The maximum drawdown of -87.48% underscores how violent the repricing has been, and the stock's behavior is now driven by post-spinoff flow dynamics rather than its pre-separation trend.
Short-term momentum remains negative but is decelerating in severity: the 1-month change of -17.65% is far less destructive than the 3-month -84.51%, and relative strength versus the S&P 500 is -12.66% over one month versus -79.60% over three months, indicating the pace of underperformance is compressing. The 1-month figure also diverges sharply from the 1-year trend in magnitude, which is consistent with a post-event mean-reversion phase rather than a fresh acceleration lower; the stock has stabilized in a $11.33–$14.45 band since early October after bottoming at $11.33 on October 28. Volume of 26.4 million shares and a short ratio of 1.38 suggest no aggressive short-squeeze setup, but also no evidence of capitulation-driven accumulation; the recent bounce from $11.33 to $12.26 on November 4 before fading to $11.90 points to fragile, headline-driven trading.
Key technical levels are well defined by the post-spinoff range: support sits at the $11.33 October 28 low, with secondary support at the 52-week low of $9.54, while resistance is the $14.45 October 7 high and then the 52-week high of $14.62. A breakout above $14.62 would signal that the market has fully absorbed the separation and is beginning to price the standalone chemistry business on fundamentals, whereas a breakdown below $11.33 would confirm the downtrend and open the door toward the $9.54 low. Beta is not available in the provided data, but the -87.48% max drawdown and the 84.5% three-month decline versus a -4.91% S&P 500 move imply realized volatility far in excess of the market, which argues for materially smaller position sizing and wider stops than a typical Basic Materials holding.
Beta
—
—
Max Drawdown
-87.5%
Largest decline past year
52-Week Range
$10-$15
Price range past year
Annual Return
-81.5%
Cumulative gain past year
| Period | CTVA Return | S&P 500 |
|---|---|---|
| 1m | -8.7% | -2.4% |
| 3m | -84.0% | -2.3% |
| 6m | -85.2% | +2.8% |
| 1y | -81.5% | +11.3% |
| ytd | -82.1% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CTVA Fundamental Analysis
Revenue is stagnating at best: Q2 2026 revenue of $6.379 billion declined 1.19% year over year versus $6.456 billion in Q2 2025, and the sequential pattern shows Q1 2026 at $4.905 billion (up from $4.417 billion in Q1 2025) followed by the Q2 contraction, indicating uneven underlying demand rather than a clean growth trajectory. Segment data shows Seed at $4.532 billion and Crop Protection at $1.847 billion, meaning the reported period still reflects a seed-heavy mix that the spin-off is designed to eliminate — post-separation, the remaining Crop Protection business represents only about 29% of the disclosed segment revenue, a critical consideration for modeling the go-forward entity. The 1.19% decline in a seasonally strong quarter, combined with consensus revenue estimates of $8.57 billion, implies the market expects modest stabilization rather than a return to growth, which caps the re-rating case until the pure-play demonstrates organic volume and price gains.
Profitability is highly seasonal and volatile: Q2 2026 net income was $1.161 billion on a 54.35% gross margin and 18.20% net margin, but Q4 2025 posted a net loss of $552 million with a -14.12% net margin and Q3 2025 lost $320 million, producing a trailing net margin of just 6.29% and a trailing EPS of $0.024. Gross margin has been improving through the cycle — from 42.35% in Q4 2025 to 51.64% in Q1 2026 to 54.35% in Q2 2026 — which is a genuine positive, and the 15.05% operating margin and 47.29% gross margin on a trailing basis are respectable for agricultural inputs, though the 4.53% ROE is weak for the sector. The key question is whether the chemistry-only business can sustain the 30.02% Q2 operating margin without the seed segment's contribution, and the trailing 6.29% net margin suggests the answer is not yet proven.
Balance sheet risk is low but cash generation is the weak link: debt-to-equity of 0.107 and a current ratio of 1.43 indicate a conservatively levered balance sheet, and interest coverage of 40.7x in Q2 2026 confirms ample debt-service capacity. However, trailing free cash flow is only $629 million against a $45.6 billion market cap, a thin 1.4% FCF yield, and the quarterly cash flow data shows severe working-capital swings — operating cash flow of -$2.891 billion in Q1 2026 and -$466 million in Q2 2026, driven by a $4.056 billion working-capital outflow in Q1. The company is funding a 1.04% dividend (payout ratio 43.4%) and buybacks ($250 million per quarter) largely from balance-sheet capacity rather than internally generated cash, which is sustainable given the low leverage but limits flexibility if the chemistry business underperforms.
Quarterly Revenue
$6.4B
2026-06
Revenue YoY Growth
-1.2%
YoY Comparison
Gross Margin
54.4%
Latest Quarter
Free Cash Flow
$629000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CTVA Overvalued?
Because trailing net income is positive but de minimis (EPS of $0.024), the trailing PE of 41.9x is economically meaningless and I have selected the forward PE of 10.59x as the primary metric, supplemented by EV/EBITDA of 14.21x and P/S of 2.62x. The gap between the 41.9x trailing and 10.59x forward multiple is enormous and implies the market expects a roughly 4x earnings recovery, consistent with consensus EPS of $0.774 versus the trailing $0.024 — a bet that the post-spinoff cost structure and normalized seasonality will restore profitability. That gap is the entire valuation thesis: if forward earnings materialize, the stock is cheap; if they disappoint, the trailing multiple is the reality.
Against the Basic Materials/Agricultural Inputs peer set, the stock screens mixed: a forward PE of 10.59x is below the low-to-mid teens typical of large-cap agrochemical peers, and P/B of 1.89x is modest, but EV/EBITDA of 14.21x is above the 8–11x range typical for the group, and P/S of 2.62x is not obviously cheap for a business with a 6.29% trailing net margin. The PEG ratio of 1.89 suggests the forward earnings growth embedded in the multiple is not being obtained at a discount, and the 1.04% dividend yield is below the sector's typical 2–3% range, offering little income support. The premium on EV/EBITDA versus the discount on forward PE reflects the market's uncertainty about the durability of EBITDA given the spin-off's segment mix change.
Historically, Corteva's own valuation band has been wide: PE ranged from 8.8x (Q2 2024) to 24.0x (Q1 2024) on positive-earnings quarters, and P/S ranged from 6.04x (Q2 2024) to 17.54x (Q3 2025), with the current P/S of 2.62x sitting at the very bottom of that historical range. The current P/B of 1.89x is near the middle of its 1.35x–2.31x historical band, while the forward PE of 10.59x is toward the lower end of the historical positive-earnings range. The read-through is that the market is pricing the pure-play chemistry business at a substantial discount to Corteva's own history — either a value opportunity if the standalone earnings power is intact, or a justified de-rating if the loss of the seed franchise permanently impairs the earnings base.
PE
6.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 9x~24x
vs. Industry Avg
14.2x
Industry PE ~14.2x*
EV/EBITDA
1.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the unproven standalone earnings base and weak cash conversion. Trailing EPS of $0.024 and a 6.29% trailing net margin sit against a consensus of $0.774, meaning roughly 97% of the forward earnings story is yet to be delivered, and the business posted net losses of $552M in Q4 2025 and $320M in Q3 2025. Trailing free cash flow of only $629M on a $45.6B market cap (1.4% FCF yield) is thin, and quarterly operating cash flow of -$2.891B in Q1 2026 and -$466M in Q2 2026 reflects severe working-capital swings that make the 43.4% payout dividend and $250M/quarter buyback dependent on balance-sheet capacity rather than internal generation. Revenue concentration adds to the risk: North America is roughly 40% of revenue and Latin America over 30%, exposing results to two regional agricultural cycles and currency moves.
Market and competitive risks are dominated by post-spinoff valuation uncertainty and flow dynamics. The stock trades at 14.21x EV/EBITDA versus the 8–11x typical for agrochemical peers, a premium that reflects doubt about EBITDA durability after the segment mix change, while the 1.89 PEG ratio suggests the forward growth is not being obtained at a discount. Realized volatility is extreme — the -87.48% max drawdown and 84.5% three-month decline versus a -4.91% S&P 500 move imply beta far above the market, so position sizing must be materially smaller than a typical Basic Materials holding. Competitive pressure in an oligopolistic crop protection market, plus the risk that index funds and separation-related holders continue to sell the stub, could keep the shares depressed regardless of fundamental improvement.
In a worst-case scenario, Q3 results show the chemistry business cannot sustain its Q2 30.02% operating margin, consensus EPS of $0.774 is cut, and the two October upgrades are reversed, triggering another leg down. The stock would likely retest the $11.33 October 28 low and then the 52-week low of $9.54, a decline of roughly -20% from the current $11.90; a break below that would put the analyst low target of $13.65 out of reach and leave the shares searching for a new floor. From $11.90, a move to the $9.54 low represents about -20% downside, while a full retracement toward the pre-spin adjusted levels is not meaningful given the structural change in the business.
FAQ
Ranked by severity: first, execution risk on the standalone earnings base — trailing EPS of $0.024 and a 6.29% trailing net margin against a $0.774 consensus mean roughly 97% of the forward story is undelivered, and the business lost $552M in Q4 2025 and $320M in Q3 2025. Second, cash generation risk — trailing FCF of $629M is a 1.4% yield on a $45.6B market cap, and operating cash flow was -$2.891B in Q1 2026 and -$466M in Q2 2026, so the 43.4% payout dividend and $250M/quarter buyback lean on balance-sheet capacity (D/E 0.107) rather than internal cash. Third, flow and sentiment risk — the stock is down 81.16% over one year with an -87.48% max drawdown, and continued index and stub-holder selling could keep it depressed regardless of fundamentals, with UBS and Citigroup still Neutral. Fourth, valuation/competitive risk — EV/EBITDA of 14.21x is above the 8–11x peer range, and in an oligopolistic crop protection market pricing pressure or a registration setback could compress the 30.02% Q2 operating margin.
The three-scenario framework assigns 50% to the base case of $13.65–$17.13, 30% to the bull case of $17.13–$20.00, and 20% to the bear case of $9.54–$11.33. The base case is most likely: revenue stabilizes near the $8.57B consensus, operating margin settles in the mid-20s rather than the 30.02% Q2 peak, and forward EPS lands somewhat below $0.774, letting the stock grind from $11.90 toward the $13.65 low target and the $17.13 average as the post-spinoff dislocation partially closes. The bull case requires Q3 to confirm standalone operating margin near 30% plus further upgrades beyond JPMorgan and KeyBanc, driving multiple expansion toward historical P/S levels and the $20.00 high target. The bear case is a Q3 margin miss that forces cuts to the $0.774 consensus, reverses the October upgrades, and breaks the $11.33 low toward $9.54. The key assumption across all three is whether the chemistry-only business can replicate the integrated margin structure.
The answer depends entirely on which earnings base you trust. On trailing numbers the stock is expensive — 41.9x trailing EPS of $0.024 — but that multiple is economically meaningless given the post-spinoff earnings trough. On forward numbers it is cheap: 10.59x the $0.774 consensus EPS sits below the low-to-mid teens typical of large-cap agrochemical peers, and P/S of 2.62x is at the very bottom of Corteva's own historical 6.04x–17.54x band. The mixed signals matter: EV/EBITDA of 14.21x is above the 8–11x peer range, P/B of 1.89x is mid-range versus its 1.35x–2.31x history, and the 1.89 PEG ratio suggests the expected growth is not being bought at a discount. Net, the market is pricing the pure-play at a substantial discount to its own history, which implies it expects either permanent impairment from losing the seed franchise or a delayed but real earnings recovery — the latter is what the sell-side is betting on.
From a pure risk/reward standpoint the setup is asymmetric but unproven: at $11.90 the stock trades 10.59x forward EPS of $0.774 and 2.62x sales, with the $17.13 average analyst target implying +44% upside and the $13.65 low target still implying +14.7%. The downside is well mapped — a retest of the $11.33 October 28 low is roughly -5%, and the $9.54 52-week low is about -20% — so the reward-to-risk skew is favorable if the forward earnings bridge holds. The catch is that trailing EPS is only $0.024 and trailing net margin 6.29%, meaning the entire bull case depends on a roughly 4x earnings recovery that no reported quarter has yet validated for the chemistry-only entity. It is a reasonable buy for risk-tolerant investors with a 12–18 month horizon who size the position small and accept Q3 event risk; it is not a good buy for income seekers (1.04% yield) or anyone needing near-term earnings visibility.
This is a medium-term, event-driven holding rather than a buy-and-forget compounder or a short-term momentum trade. The stock is in a severe structural downtrend — down 81.16% over one year and 84.51% over three months, with an -87.48% max drawdown — and its realized volatility is far in excess of the market, so short-term trading carries wide gap risk around Q3 and any analyst revisions. At the same time, the 1.04% dividend yield (43.4% payout) is too thin to anchor a long-term income thesis, and the 4.53% ROE is weak for the sector, so the return case rests on multiple re-rating rather than compounding. A concrete minimum holding period of 12–18 months is appropriate, long enough to see Q3 and at least two more quarters of pure-play results confirm or refute the $0.774 EPS bridge, with position sizing materially smaller than a typical Basic Materials allocation and a defined stop below the $11.33 October 28 low.